Compare trend and price ARGX vs ARRY
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and ARRY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARGX’s FA Score shows that 1 FA rating(s) are green whileARRY’s FA Score has 1 green FA rating(s).
- ARGX’s FA Score: 1 green, 4 red.
- ARRY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARGX’s TA Score shows that 4 TA indicator(s) are bullish while ARRY’s TA Score has 4 bullish TA indicator(s).
- ARGX’s TA Score: 4 bullish, 6 bearish.
- ARRY’s TA Score: 4 bullish, 6 bearish.
Price Growth
ARGX (@Biotechnology) experienced а +2.84% price change this week, while ARRY (@Electrical Products) price change was +8.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.51%. For the same industry, the average monthly price growth was -3.37%, and the average quarterly price growth was +1265.61%.
The average weekly price growth across all stocks in the @Electrical Products industry was +2.99%. For the same industry, the average monthly price growth was +91.28%, and the average quarterly price growth was +308.25%.
Reported Earning Dates
ARGX is expected to report earnings on Jul 25, 2024.
ARRY is expected to report earnings on Aug 06, 2024.
Industries' Descriptions
@Biotechnology (+7.51% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Electrical Products (+2.99% weekly)The industry produces a diverse range of electricity-powered equipment, appliances and components, catering to both households and industries. The products include power, distribution and specialty transformers; electric motors, generators and motor-generator sets; switchgear and switchboard apparatus; light bulbs, tubes, fittings and electric signs etc. Consumer income, construction spending, and industrial production are major drivers of demand for this industry’s products. Large companies tend to have economies of scale in production, marketing, and distribution, while smaller companies can potentially carve out their own market through niche or specialty offerings. The US electrical products manufacturing industry includes about 5,700 establishments (single-location companies and units of multi-location companies) with combined annual revenue of about $125 billion. (according to a study published in First Research). Emerson Electric Co., Hubbell Incorporated and Eaton Corporation plc are major electrical products makers in the U.S.
| ARGX | ARRY | ARGX / ARRY | |
| Capitalization | 22.3B | 2.22B | 1,004% |
| EBITDA | N/A | 276M | - |
| Gain YTD | -3.110 | -28.929 | 11% |
| P/E Ratio | N/A | 26.23 | - |
| Revenue | N/A | 1.58B | - |
| Total Cash | N/A | 249M | - |
| Total Debt | N/A | 730M | - |
ARGX | ARRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 25 | 100 | |
SMR RATING 1..100 | 93 | 22 | |
PRICE GROWTH RATING 1..100 | 75 | 84 | |
P/E GROWTH RATING 1..100 | 100 | 99 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARGX's Valuation (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARRY (94) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ARRY’s over the last 12 months.
ARGX's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for ARRY (100) in the Biotechnology industry. This means that ARGX’s stock grew significantly faster than ARRY’s over the last 12 months.
ARRY's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for ARGX (93) in the Pharmaceuticals Other industry. This means that ARRY’s stock grew significantly faster than ARGX’s over the last 12 months.
ARGX's Price Growth Rating (75) in the Pharmaceuticals Other industry is in the same range as ARRY (84) in the Biotechnology industry. This means that ARGX’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ARGX (100) in the Pharmaceuticals Other industry. This means that ARRY’s stock grew similarly to ARGX’s over the last 12 months.
| ARGX | ARRY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 85% |
| Advances ODDS (%) | 4 days ago 69% | 3 days ago 79% |
| Declines ODDS (%) | 2 days ago 67% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 66% |
| Aroon ODDS (%) | 2 days ago 46% | 2 days ago 89% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PORIX | 57.83 | -0.09 | -0.16% |
| Trillium ESG Global Equity Institutional | |||
| GVMCX | 42.21 | -0.10 | -0.24% |
| Government Street Opportunities | |||
| GCPNX | 17.64 | -0.06 | -0.34% |
| Gateway Equity Call Premium N | |||
| VLISX | 480.11 | -2.16 | -0.45% |
| Vanguard Large Cap Index Institutional | |||
| BGEFX | 12.52 | -0.14 | -1.11% |
| Baillie Gifford International Growth 4 | |||
ARGX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with BBIO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then BBIO could also see price increases.
| Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
|---|---|---|---|---|
| ARGX | 100% | -1.71% | ||
| BBIO - ARGX | 51% Loosely correlated | -2.80% | ||
| NRBO - ARGX | 45% Loosely correlated | -1.29% | ||
| MDGL - ARGX | 43% Loosely correlated | -5.02% | ||
| BLUE - ARGX | 42% Loosely correlated | -1.13% | ||
| AXON - ARGX | 40% Loosely correlated | +1.27% | ||
More | ||||